Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612

Infections, Meningococcal Clinical Trial

Official title:

Non-inferiority of GSK Biologicals' Meningococcal Vaccine 134612 Given Concomitantly With GSK Biologicals' Twinrix™ Versus 134612 Alone and Twinrix™ Alone in Healthy Subjects Aged 11 Through 17 Years.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00465816
• Other study ID #: 109063
• Status: Completed
• Phase: Phase 3
• Start date: April 11, 2007
• Est. completion date: April 28, 2008

Study information

• Verified date: November 2016
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will demonstrate the non-inferiority of GSK Biologicals' meningococcal vaccine 134612 when given in an experimental co-administration versus vaccine 134612 alone and versus the experimental co-administration alone in healthy subjects aged 11 through 17 years. There will be 3 groups in this study.

Description:

All subjects of groups A and B will have 4 blood samples taken, all subjects of group C will have 3 blood samples taken.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, September 2007.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 611
• Est. completion date: April 28, 2008
• Est. primary completion date: April 28, 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 11 Years to 17 Years

Eligibility

Inclusion Criteria:

• Subjects who the investigator believes that they and/or their parents/guardians can and will comply with the requirements of the protocol

• A male or female between, and including, 11 and 17 years of age at the time of the first dose of vaccine.

• Written informed consent obtained from the subject/ from the parent or guardian of the subject.

• Healthy subjects as established by medical history and clinical examination before entering into the study.

• Previously completed routine childhood vaccinations to the best of his/her/the parents'/guardians' knowledge.

• If the subject is female and of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series.

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.

• Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine.

• Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C, W-135 and/or Y within the last five years.

• Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroup A, C, W-135 and/or Y.

• Previous vaccination with tetanus toxoid within the last month.

• Previous vaccination with hepatitis A and/or hepatitis B vaccine.

• Seropositivity for hepatitis A IgG, hepatitis B surface antigen, hepatitis B core antibody and/or hepatitis B surface antigen at screening.

• History of hepatitis A, hepatitis B and/or Neisseria meningitidis infection.

• Known exposure to hepatitis A and/or hepatitis B virus within three months preceding the first dose of study vaccine.

• Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination.

• A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.

• History of reactions or allergic disease likely to be exacerbated by any component of either vaccine.

• Major congenital defects or serious chronic illness.

• Acute disease at the time of enrolment.

• Administration of immunoglobulins and/or any blood products within the three months preceding the dose of study vaccine or planned administration during the study period.

• Pregnant or lactating female.

• History of chronic alcohol consumption and/or drug abuse.

• Female planning to become pregnant or planning to discontinue contraceptive precautions.

Related Conditions & MeSH terms

• Infections, Meningococcal
• Meningococcal Infections

Intervention

Biological:
• Nimenrix (Meningococcal vaccine 134612)
Single dose intramuscular injection
• Twinrix
3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.

Locations

Country	Name	City	State
Denmark	GSK Investigational Site	Aarhus N
Sweden	GSK Investigational Site	Karlskrona
Sweden	GSK Investigational Site	Linköping
Sweden	GSK Investigational Site	Malmö
Sweden	GSK Investigational Site	Örebro
Sweden	GSK Investigational Site	Umeå

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Denmark,  Sweden, 

References & Publications (2)

Ostergaard L et al. The Candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugated vaccine (MenACWY-TT) co-administered with a combined hepatitis A and B vaccine (HepA/B) is immunogenic with an acceptable safety profile in subjects aged 11-17 Years. Abstract presented at the 3rd Northern European Conference on Travel Medicine (NECTM). Hamburg, Germany, 26-29 May 2010.

Østergaard L, Silfverdal SA, Berglund J, Flodmark CE, West C, Bianco V, Baine Y, Miller JM. A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix(®) in subjects aged 11-17 years: an open, randomised, controlled trial. Vaccine. 2012 Jan 17;30(4):774-83. doi: 10.1016/j.vaccine.2011.11.051. Epub 2011 Nov 19. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Meningococcal Polysaccharide A Serum Bactericidal Antibodies/Assay, Using Baby Rabbit Complement for Assay (rSBA-MenA), rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers	The rSBA titers were expressed as geometric mean titers (GMTs).	At 1 month after vaccination with Nimenrix vaccine (Month 1)
Primary	Number of Subjects Seroconverted for Hepatitis A	A seroconverted subject was defined as a subject with anti-Hepatitis A virus (HAV) antibody concentration greater than or equal to 15 milli-International Units per Milliliter (mIU/mL) in previously seronegative subjects.	At 1 month after the third dose of Twinrix vaccine (Month 7)
Primary	Number of Subjects Seroprotected for Hepatitis B	A seroprotected subject was defined as a subject with anti-Hepatitis B surface antigen (HBs) antibody concentration greater than or equal to 10 milli-International Units per Milliliter (mIU/mL).	At 1 month after the third dose of Twinrix vaccine (Month 7)
Secondary	Number of Subjects With a Vaccine Response to MenA, MenC, MenY and MenW-135	Vaccine response is defined as an rSBA titer of at least 1:32 in subjects initially seronegative [rSBA titer below1:8] and as a 4-fold increase in titer in subjects initially seropositive [rSBA titre greater than or equal to 1:8].	At 1 month after vaccination with Nimenrix vaccine (Month 1)
Secondary	Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers Above Predefined Cut-off Values	The cut-off values assessed were greater than or equal to (=) 1:8 and = 1:128.	Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)
Secondary	Anti-PSA (Polysaccharide A), Anti-PSC (Polysaccharide C), Anti-PSW-135 (Polysaccharide W-135), and Anti-PSY (Polysaccharide Y) Antibody Concentrations	Concentrations were provided as Geometric Mean Concentrations expressed as micrograms per milliliter (µg/mL).	Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)
Secondary	Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135, and Anti-PSY Antibody Concentrations Above Pre-defined Cut-off Values	The cut-off values assessed include greater than or equal to (=) 0.3 micrograms per milliliter (µg/mL) and = 2.0 µg/mL.	Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)
Secondary	Anti-Tetanus Toxoid (TT) Antibody Concentrations	Concentrations were provided as Geometric Mean Concentrations expressed as International Units per milliliter (IU/mL).	Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)
Secondary	Number of Subjects With Anti-tetanus Toxoid Antibody Concentrations Above the Pre-defines Cut-off Value	The cut-off value assessed was greater than or equal to 0.1 International Units per milliliter (IU/mL).	Prior to and 1 month after vaccination with Nimenrix vaccine (Months 0 and 1)
Secondary	rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers at Month 7	The rSBA titers were expressed as geometric mean titers.	At 7 months after vaccination with Nimenrix (At Month 7)
Secondary	Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers Above Predefined Cut-off Values at Month 7	The cut-off values assessed were greater than or equal to (=) 1:8 and = 1:128.	At 7 months after vaccination with Nimenrix (At Month 7)
Secondary	Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations at Month 7	Concentrations were provided as Geometric Mean Concentrations expressed as micrograms per milliliter (µg/mL).	At 7 months after vaccination with Nimenrix (At Month 7)
Secondary	Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations Above Pre-defined Cut-off Values at Month 7	The cut-off values assessed include greater than or equal to (=) 0.3 micrograms per milliliter (µg/mL) and = 2.0 µg/mL.	At 7 months after vaccination with Nimenrix (At Month 7)
Secondary	Immunoglobulin G (IgG) Anti-HAV Antibody Concentrations	Concentrations are given as Geomatric Mean Concentrations expressed as milli-Internatinal Units per Milliliter (mIU/mL).	Prior to the first dose (Month 0) and 1 month after the third dose of Twinrix vaccine (Month 7)
Secondary	Number of Subjects With IgG Anti-HAV Antibody Concentrations Above the Pre-defined Cut-off Value	The cut-off value assessed was greater than or equal to 15 milli-Internatinal Units per Milliliter (mIU/mL).	Prior to the first dose (Month 0) and 1 month after the third dose of Twinrix vaccine (Month 7)
Secondary	IgG Anti-HBs Antibody Concentrations	Concentrations are given as Geomatric Mean Concentrations expressed as milli-Internatinal Units per Milliliter (mIU/mL).	Prior to the first dose (Month 0) and 1 month after the third dose of Twinrix vaccine (Month 7)
Secondary	Number of Subjects With IgG Anti-HB Antibody Concentrations Above the Pre-defined Cut-off Value	The cut-off value assessed was greater than or equal to 10 milli-Internatinal Units per Milliliter (mIU/mL).	Prior to the first dose (Month 0) and 1 month after the third dose of Twinrix vaccine (Month 7)
Secondary	Number of Subjects Reporting Any Solicited Local Symptoms Post-meningococcal Vaccination	Solicited local symptoms assessed include pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.	During a 4-day period (Days 0-3) after Nimenrix vaccination
Secondary	Number of Subjects Reporting Any Solicited Local Symptoms Post-Twinrix Vaccination	Solicited local symptoms assessed include pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.	During a 4-day period (Days 0-3) after each Twinrix vaccination, and across doses
Secondary	Number of Subjects Reporting Any Solicited General Symptoms	Solicited general symptoms assessed include fatigue, fever (axillary temperature greater than or equal to 37.5 degrees Celcius), gastrointestinal symptoms and headache. Any = occurrence of the symptom regardless of intensity grade. Dose 1 = post-Nimenrix and post-Twinrix for the Nimenrix + Twinrix Group, post-Twinrix for the Twinrix Group and post-Nimenrix for the Nimenrix Group, Dose 2, 3 and Across doses = post-Twinrix for the Nimenrix + Twinrix Group and for the Twinrix Group.	During a 4-day period (Days 0-3) after each vaccine dose and across doses
Secondary	Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)	Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.	Up to 1 month after each vaccine dose
Secondary	Number of Subjects Reporting Any Specific AEs of New Onset of Chronic Illnesses	Specific AEs of new onset of chronic illnesses include e.g. autoimmune disorders, asthma, type I diabetes and allergies.	During the entire study (up to Month 7)
Secondary	Number of Subjects Reporting Any Rash	Rashes include e.g. hives, idiopathic thrombocytopenic purpura, petechiae.	During the entire study (up to Month 7)
Secondary	Number of Subjects Reporting Any Conditions Prompting Emergency Room Visits		During the entire study (up to Month 7)
Secondary	Number of Subjects Reporting Any Serious Adverse Events (SAEs)	SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.	During the entire study (up to Month 7)

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.